This approach was inspired by the metabolic disorder type I hereditary tyrosinemia, in which the absence of fumarylacetoacetate hydrolase leads to the accumulation of the hepatotoxic metabolite fumarylacetoacetate and ultimately to liver failure (57). The gene discussed is FAH; the disease is liver failure.